Sabina Signoretti

Sabina Signoretti

Harvard University

H-index: 115

North America-United States

About Sabina Signoretti

Sabina Signoretti, With an exceptional h-index of 115 and a recent h-index of 83 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Molecular Pathology of genitourinary malignancies.

His recent articles reflect a diverse array of research interests and contributions to the field:

Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model

Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled …

Establishing orthotopic renal cell carcinoma xenograft in PBMC-humanized immunodeficient NSG-MHC I/II double knock-out mice

Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation.

Sabina Signoretti Information

University

Position

Professor, Brigham and Women's Hospital, Harvard Medical School

Citations(all)

65961

Citations(since 2020)

43629

Cited By

39002

hIndex(all)

115

hIndex(since 2020)

83

i10Index(all)

256

i10Index(since 2020)

212

Email

University Profile Page

Harvard University

Google Scholar

View Google Scholar Profile

Sabina Signoretti Skills & Research Interests

Molecular Pathology of genitourinary malignancies

Top articles of Sabina Signoretti

Title

Journal

Author(s)

Publication Date

Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model

Iscience

Yufei Wang

Jae-Won Cho

Gabriella Kastrunes

Alicia Buck

Cecile Razimbaud

...

2024/2/16

Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.

Eddy Saad

Chris Labaki

Benjamin Miron

Jihye Park

Ziad Bakouny

...

2024/2/1

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Clinical Cancer Research

Thomas Denize

Opeyemi A Jegede

Sayed Matar

Nourhan El Ahmar

Destiny J West

...

2024/2/16

Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).

Michael Thomas Serzan

Opeyemi Jegede

Mehmet Asim Bilen

David A Braun

David Johnson Einstein

...

2024/2/1

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Cancer Cell

Renée Maria Saliby

Chris Labaki

Tejas R Jammihal

Wanling Xie

Maxine Sun

...

2024/3/22

Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled …

Nourhan El Ahmar

Sayed Matar

Opeyemi Jegede

Yasmin Nabil Laimon

Varunika Savla

...

2024/2/1

Establishing orthotopic renal cell carcinoma xenograft in PBMC-humanized immunodeficient NSG-MHC I/II double knock-out mice

Cancer Research

Wonyoung Kang

Yufei Wang

Yasmin N Laimon

Oanh Pham

Ben Matran

...

2024/3/22

Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation.

Karl Semaan

Talal El Zarif

Ji-Heui Seo

Marc Eid

John Canniff

...

2024/2/1

Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC).

Chris Labaki

Michel Alchoueiry

Kevin Bi

Long Zhang

Charbel Hobeika

...

2024/2/1

Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects

Molecular Cancer

Yufei Wang

Alicia Buck

Brandon Piel

Luann Zerefa

Nithyassree Murugan

...

2024/3/16

Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockade

Cancer Research

Miya B Hugaboom

Neil Ruthen

Opeyemi Jegede

Nicholas R Schindler

Lena Wirth

...

2023/8/15

KDM6A epigenetically regulates subtype plasticity in small cell lung cancer

Nature Cell Biology

Leslie Duplaquet

Yixiang Li

Matthew A Booker

Yingtian Xie

Sarah Naomi Olsen

...

2023/9

Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy.

David A Braun

Kelly Street

Opeyemi Jegede

Neil Ruthen

Miya Hugaboom

...

2023/2/20

Regulation of HHLA2 expression in kidney cancer and myeloid cells

BMC cancer

Tomonari Shigemura

Nahuel Perrot

Zimo Huang

Rupal S Bhatt

Aseman Bagheri Sheshdeh

...

2023/10/27

Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 …

David A Braun

Kelly Street

Opeyemi Jegede

Neil Ruthen

Miya Hugaboom

...

2023/6/1

Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing

Nature genetics

Isidro Cortés-Ciriano

Jake June-Koo Lee

Ruibin Xi

Dhawal Jain

Youngsook L Jung

...

2023/6

Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma

Cancer Immunology Research

Renee Maria Saliby

Talal El Zarif

Ziad Bakouny

Valisha Shah

Wanling Xie

...

2023/8/3

Abstract A005: Regulation of HHLA2 expression in renal cell carcinoma and myeloid cells

Cancer Research

Tomonari Shigemura

Nahuel Perrot

Zimo Huang

Aseman Bagheri Sheshdeh

Nourhan El Ahmar

...

2023/8/15

Author Correction: The evolutionary history of 2,658 cancers (Nature,(2020), 578, 7793,(122-128), 10.1038/s41586-019-1907-7)

Nature

Moritz Gerstung

Clemency Jolly

Ignaty Leshchiner

Stefan C Dentro

Santiago Gonzalez

...

2023/2/16

1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma

Annals of Oncology

RM Saliby

T Jammihal

C Labaki

H Soulati

J Gallegos

...

2023/10/1

See List of Professors in Sabina Signoretti University(Harvard University)